The National Cancer Institute's Small Business Innovation Research Development Center this week announced $10 million in new contract funding opportunities, including several for proteomics research reagents.
Specifically, NCI called for proposals for technology to generate anti-peptide affinity agents for proteomic studies using techniques such as SISCAPA.
Development of the reagents is to be done in coordination with the NCI's Clinical Proteomic Technologies for Cancer initiative. In the first phase of the contract, which is budgeted for $200,000 and nine months, awardees will be expected to develop high-affinity, high-specificity reagents against 10 different peptides. In the second phase, which is budgeted for $1 million and two years, awardees are expected to develop at least 100 anti-peptide capture agents in coordination with the CPTC and work to integrate them into proteomic research platforms.
Funding is also available for the development of human tissue culture systems mimicking the tumor microenvironment; development of standards for metabolomics research; and development of chemically defined glycan libraries for reference standards and glycomics research.
Applications are due by Nov. 13.